Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Monica Fay"'
Autor:
ANDERSON, MONICA FAY
Publikováno v:
Theatre Journal, 2017 Dec 01. 69(4), 578-580.
Externí odkaz:
https://www.jstor.org/stable/48560831
Autor:
Jacqueline Nicholas, Wei-Shi Yeh, Ming-Yi Huang, Ning Wu, Andrew Lee, Aaron Boster, Jon Kendter, Monica Fay
Publikováno v:
PharmacoEconomics Open
Background Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose
Autor:
Ming-Yi Huang, Monica Fay, Ning Wu, Michael R. Edwards, Andrew Lee, Jacqueline Nicholas, Wei-Shi Yeh, Aaron Boster
Publikováno v:
Neurology and Therapy
Introduction Limited data are available on the real-world effectiveness of newer oral disease-modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to retrospectively compare the real-world effectiveness of dimethyl fumarate
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:1385-1391
Multiple sclerosis (MS) is a chronic and debilitating disease of the central nervous system that affects more than 570,000 persons in the United States and 2.3 million worldwide. Since most individuals experience initial symptoms between the ages of
Publikováno v:
Journal of Medical Economics. 19:684-695
Objective Peginterferon beta-1a 125 mcg, administered subcutaneously (SC) every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved by the US Food and Drug Administration in 2014. This study
Autor:
Monica Fay Anderson
Publikováno v:
Theatre Journal. 69:578-580
Autor:
Brieana Cox-Buckley, Michaela Calnan, Ravi Iyer, Matthew Davis, Mei Sheng Duh, Sujata P. Sarda, S. Yermakov, Monica Fay
Publikováno v:
Journal of Medical Economics. 18:711-720
To estimate the effect of adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) on healthcare resource utilization (HRU) and costs, and model the impact of a 10 percentage point increase in adherence on these out
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Objective: To assess the cost-effectiveness of delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF), an effective therapy for relapsing forms of multiple sclerosis (MS), compared with glatiramer acetate and fingolimod, commonly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::029bc226e27cd215e5f726613858e342
Autor:
Monica Fay Anderson
Publikováno v:
Theatre Journal. 60:294-298